STOCK TITAN

[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4

Director Paul Steven M reported purchases of Rapport Therapeutics, Inc. (RAPP) common stock on 09/12/2025. Two purchase entries show 28,284 shares at a weighted average price of $24.4996 and 13,382 shares at a weighted average price of $24.9712, for a combined 41,666 shares. Both holdings are reported as indirect ownership through Paul Capital Strategy III Fund LLC, with the reporting person disclaiming beneficial ownership except to the extent of any pecuniary interest. The filing discloses the price ranges for the multiple trades that produced the weighted averages and is signed by an attorney-in-fact on behalf of the reporting person.

Il direttore Paul Steven M ha riportato l'acquisto di azioni ordinarie di Rapport Therapeutics, Inc. (RAPP) il 12/09/2025. Due inserimenti di acquisto mostrano 28.284 azioni a un prezzo medio ponderato di $24,4996 e 13.382 azioni a un prezzo medio ponderato di $24,9712, per un totale combinato di 41.666 azioni. Entrambe le partecipazioni sono riportate come proprietà indiretta tramite Paul Capital Strategy III Fund LLC, con la persona che riporta che rinuncia alla proprietà benefica salvo l'interesse economico in misura necessaria. Il deposito rivela i range di prezzo per le molteplici operazioni che hanno prodotto le medie ponderate ed è firmato da un procuratore (avvocato-in-fatto) per conto della persona che riporta.

El director Paul Steven M informó compras de acciones ordinarias de Rapport Therapeutics, Inc. (RAPP) el 12/09/2025. Dos entradas de compra muestran 28.284 acciones a un precio medio ponderado de $24,4996 y 13.382 acciones a un precio medio ponderado de $24,9712, para un total combinado de 41.666 acciones. Ambas participaciones se reportan como propiedad indirecta a través de Paul Capital Strategy III Fund LLC, con la persona informante renunciando a la titularidad beneficiosa salvo en la medida de cualquier interés pecuniario. El documento revela los rangos de precios para las múltiples operaciones que dieron lugar a las medias ponderadas y está firmado por un apoderado (abogado-in-fact) en nombre de la persona reportante.

Paul Steven M 이 2025년 9월 12일 Rapport Therapeutics, Inc. (RAPP) 보통주 매입을 보고했습니다. 두 건의 매입 내역은 각각 28.284주를 $24,4996의 가중평균가로, 그리고 13.382주를 $24,9712의 가중평균가로 표시하며, 합계는 41.666주입니다. 두 보유 지분 모두 Paul Capital Strategy III Fund LLC를 통한 간접 소유로 보고되며, 보고자는 재정적 이해관계 범위를 제외하고 유익한 소유권을 포기합니다. 이 서류는 가중 평균을 산출한 다수의 거래에 대한 가격 범위를 공개하며, 보고를 대리하는 대리인(대리권을 가진 변호사)이 서명하였습니다.

Le directeur Paul Steven M a signalé des achats d'actions ordinaires de Rapport Therapeutics, Inc. (RAPP) le 12/09/2025. Deux entrées d'achat indiquent 28.284 actions à un prix moyen pondéré de $24,4996 et 13.382 actions à un prix moyen pondéré de $24,9712, pour un total combiné de 41.666 actions. Les deux participations sont déclarées comme une propriété indirecte via Paul Capital Strategy III Fund LLC, le déclarant déclinant toute propriété bénéficiaire à l'exception de tout intérêt pécuniaire. Le dépôt révèle les plages de prix pour les multiples transactions qui ont produit les moyennes pondérées et est signé par un mandataire (avocat-in-fait) au nom de la personne qui déclare.

Der Direktor Paul Steven M hat Käufe von Stammaktien von Rapport Therapeutics, Inc. (RAPP) am 12.09.2025 gemeldet. Zwei Kaufvorgänge zeigen 28.284 Aktien zu einem gewichteten Durchschnittspreis von $24,4996 und 13.382 Aktien zu einem gewichteten Durchschnittspreis von $24,9712, insgesamt 41.666 Aktien. Beide Bestände werden als indirekt Eigentum durch den Paul Capital Strategy III Fund LLC gemeldet, wobei der meldende Person erklärt, kein wirtschaftliches Eigentum zu besitzen, außer in dem Umfang, wie sie wirtschaftliche Interessen hat. Die Einreichung offenbart die Preisspannen für die mehreren Trades, die die gewichteten Durchschnitte erzeugt haben, und ist von einem Bevollmächtigten im Namen der meldenden Person unterschrieben.

ذكر المخرج بول ستيفن م شراء أسهم عادية من Rapport Therapeutics, Inc. (RAPP) في 12/09/2025. يظهر إدخالا شراءان 28.284 سهماً بسعر متوسط موزون قدره $24,4996 و 13.382 سهماً بسعر مُوزون قدره $24,9712، لمجموع 41.666 سهماً. يتم الإبلاغ عن كلا الحيازتين كملكية غير مباشرة من خلال Paul Capital Strategy III Fund LLC، مع إنكار الشخص المبلغ له الملكية المفيدة إلى الحد الذي يتقاطع فيه مع أي مصلحة مالية. تكشف الإيداع عن نطاقات الأسعار للصفقات المتعددة التي أدت إلى المتوسطات الموزونة، وهو موقع من قبل موكل/محامٍ بالوكالة نيابة عن الشخص المبلغ.

董事保罗·史蒂文·M在2025-09-12报告了对 Rapport Therapeutics, Inc. (RAPP)普通股的购买。两笔购买记录显示28,284股,加权平均价格为$24,4996,以及13,382股,加权平均价格为$24,9712,合计共计41,666股。两项持股均通过Paul Capital Strategy III Fund LLC被报告为间接所有权,申报人除对任何经济利益的范围外,否认具有受益所有权。该文件披露了产生加权平均数的多笔交易的价格区间,并由代表申报人的代理律师签署。

Positive
  • Director-associated purchases totaling 41,666 shares were reported, indicating acquisition activity by an insider-affiliated fund
  • Full transaction detail provided with weighted average prices and price ranges for the multiple executions
Negative
  • None.

Insights

Insider purchases reported: a director acquired 41,666 shares indirectly via an affiliated investment fund.

The Form 4 records purchases executed on 09/12/2025 totaling 41,666 common shares acquired at weighted average prices of $24.4996 and $24.9712. Transactions are reported as indirect through Paul Capital Strategy III Fund LLC, which means the reported director is associated with the fund rather than holding the shares directly. The filing provides weighted-average price ranges for the multiple executions and includes the standard disclaimer of beneficial ownership except for any pecuniary interest.

Routine SEC disclosure of director-related fund purchases; indirect ownership and disclaimer are properly disclosed.

The filing follows Section 16 reporting conventions by listing transaction codes, weighted-average prices, and the nature of indirect ownership via an affiliated fund. The reporting person checked the director box and filed as one reporting person. The disclosure and signature by an attorney-in-fact indicate procedural compliance; no additional governance actions or departures are reported in this form.

Il direttore Paul Steven M ha riportato l'acquisto di azioni ordinarie di Rapport Therapeutics, Inc. (RAPP) il 12/09/2025. Due inserimenti di acquisto mostrano 28.284 azioni a un prezzo medio ponderato di $24,4996 e 13.382 azioni a un prezzo medio ponderato di $24,9712, per un totale combinato di 41.666 azioni. Entrambe le partecipazioni sono riportate come proprietà indiretta tramite Paul Capital Strategy III Fund LLC, con la persona che riporta che rinuncia alla proprietà benefica salvo l'interesse economico in misura necessaria. Il deposito rivela i range di prezzo per le molteplici operazioni che hanno prodotto le medie ponderate ed è firmato da un procuratore (avvocato-in-fatto) per conto della persona che riporta.

El director Paul Steven M informó compras de acciones ordinarias de Rapport Therapeutics, Inc. (RAPP) el 12/09/2025. Dos entradas de compra muestran 28.284 acciones a un precio medio ponderado de $24,4996 y 13.382 acciones a un precio medio ponderado de $24,9712, para un total combinado de 41.666 acciones. Ambas participaciones se reportan como propiedad indirecta a través de Paul Capital Strategy III Fund LLC, con la persona informante renunciando a la titularidad beneficiosa salvo en la medida de cualquier interés pecuniario. El documento revela los rangos de precios para las múltiples operaciones que dieron lugar a las medias ponderadas y está firmado por un apoderado (abogado-in-fact) en nombre de la persona reportante.

Paul Steven M 이 2025년 9월 12일 Rapport Therapeutics, Inc. (RAPP) 보통주 매입을 보고했습니다. 두 건의 매입 내역은 각각 28.284주를 $24,4996의 가중평균가로, 그리고 13.382주를 $24,9712의 가중평균가로 표시하며, 합계는 41.666주입니다. 두 보유 지분 모두 Paul Capital Strategy III Fund LLC를 통한 간접 소유로 보고되며, 보고자는 재정적 이해관계 범위를 제외하고 유익한 소유권을 포기합니다. 이 서류는 가중 평균을 산출한 다수의 거래에 대한 가격 범위를 공개하며, 보고를 대리하는 대리인(대리권을 가진 변호사)이 서명하였습니다.

Le directeur Paul Steven M a signalé des achats d'actions ordinaires de Rapport Therapeutics, Inc. (RAPP) le 12/09/2025. Deux entrées d'achat indiquent 28.284 actions à un prix moyen pondéré de $24,4996 et 13.382 actions à un prix moyen pondéré de $24,9712, pour un total combiné de 41.666 actions. Les deux participations sont déclarées comme une propriété indirecte via Paul Capital Strategy III Fund LLC, le déclarant déclinant toute propriété bénéficiaire à l'exception de tout intérêt pécuniaire. Le dépôt révèle les plages de prix pour les multiples transactions qui ont produit les moyennes pondérées et est signé par un mandataire (avocat-in-fait) au nom de la personne qui déclare.

Der Direktor Paul Steven M hat Käufe von Stammaktien von Rapport Therapeutics, Inc. (RAPP) am 12.09.2025 gemeldet. Zwei Kaufvorgänge zeigen 28.284 Aktien zu einem gewichteten Durchschnittspreis von $24,4996 und 13.382 Aktien zu einem gewichteten Durchschnittspreis von $24,9712, insgesamt 41.666 Aktien. Beide Bestände werden als indirekt Eigentum durch den Paul Capital Strategy III Fund LLC gemeldet, wobei der meldende Person erklärt, kein wirtschaftliches Eigentum zu besitzen, außer in dem Umfang, wie sie wirtschaftliche Interessen hat. Die Einreichung offenbart die Preisspannen für die mehreren Trades, die die gewichteten Durchschnitte erzeugt haben, und ist von einem Bevollmächtigten im Namen der meldenden Person unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
PAUL STEVEN M

(Last) (First) (Middle)
RAPPORT THERAPEUTICS, INC.
99 HIGH STREET, SUITE 2100

(Street)
BOSTON MA 02110

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/12/2025 P 28,284 A $24.4996(1) 28,284 I By Paul Capital Strategy III Fund LLC(2)
Common Stock 09/12/2025 P 13,382 A $24.9712(3) 41,666 I By Paul Capital Strategy III Fund LLC(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $23.90 to $24.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
2. Shares held by Paul Capital Strategy III Fund LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $24.90 to $25.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
/s/ Troy Ignelzi, Attorney-in-Fact 09/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Paul Steven M report for RAPP on 09/12/2025?

The filing reports purchases of 28,284 shares at a weighted average price of $24.4996 and 13,382 shares at a weighted average price of $24.9712, totaling 41,666 shares acquired on 09/12/2025.

Are the shares held directly by the director in the RAPP Form 4?

No. Both entries are reported as indirect ownership by Paul Capital Strategy III Fund LLC, and the reporting person disclaims beneficial ownership except for any pecuniary interest.

What price ranges produced the weighted average prices in the RAPP Form 4?

For the 28,284-share block prices ranged from $23.90 to $24.89. For the 13,382-share block prices ranged from $24.90 to $25.00.

Who signed the Form 4 for the reporting person?

The form is signed by /s/ Troy Ignelzi, Attorney-in-Fact on behalf of the reporting person, dated 09/15/2025.
Rapport Therapeutics Inc

NASDAQ:RAPP

RAPP Rankings

RAPP Latest News

RAPP Latest SEC Filings

RAPP Stock Data

1.32B
43.85M
6.26%
106.26%
8.62%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON